GB0404187D0 - Binding agents - Google Patents

Binding agents

Info

Publication number
GB0404187D0
GB0404187D0 GBGB0404187.7A GB0404187A GB0404187D0 GB 0404187 D0 GB0404187 D0 GB 0404187D0 GB 0404187 A GB0404187 A GB 0404187A GB 0404187 D0 GB0404187 D0 GB 0404187D0
Authority
GB
United Kingdom
Prior art keywords
binding agents
binding
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0404187.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOTRANSFORMATIONS Ltd
Original Assignee
BIOTRANSFORMATIONS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOTRANSFORMATIONS Ltd filed Critical BIOTRANSFORMATIONS Ltd
Priority to GBGB0404187.7A priority Critical patent/GB0404187D0/en
Publication of GB0404187D0 publication Critical patent/GB0404187D0/en
Priority to JP2007500291A priority patent/JP2007524105A/ja
Priority to US10/590,840 priority patent/US20080107660A1/en
Priority to EP05717788A priority patent/EP1723418A2/en
Priority to PCT/GB2005/000704 priority patent/WO2005083431A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
GBGB0404187.7A 2004-02-25 2004-02-25 Binding agents Ceased GB0404187D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0404187.7A GB0404187D0 (en) 2004-02-25 2004-02-25 Binding agents
JP2007500291A JP2007524105A (ja) 2004-02-25 2005-02-25 結合物質
US10/590,840 US20080107660A1 (en) 2004-02-25 2005-02-25 Binding Agents
EP05717788A EP1723418A2 (en) 2004-02-25 2005-02-25 Binding agents
PCT/GB2005/000704 WO2005083431A2 (en) 2004-02-25 2005-02-25 Binding agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0404187.7A GB0404187D0 (en) 2004-02-25 2004-02-25 Binding agents

Publications (1)

Publication Number Publication Date
GB0404187D0 true GB0404187D0 (en) 2004-03-31

Family

ID=32050854

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0404187.7A Ceased GB0404187D0 (en) 2004-02-25 2004-02-25 Binding agents

Country Status (5)

Country Link
US (1) US20080107660A1 (enExample)
EP (1) EP1723418A2 (enExample)
JP (1) JP2007524105A (enExample)
GB (1) GB0404187D0 (enExample)
WO (1) WO2005083431A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547324B2 (ja) * 2005-11-24 2010-09-22 シャープ株式会社 タンパク質認識構造体、タンパク質認識基板、及びこれらの製造方法
GB0707870D0 (en) 2007-04-23 2007-05-30 Selected Antibodies Ltd Assay Devices and Methods and Components for use Therein
GB0716160D0 (en) * 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010077643A1 (en) * 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
US8895702B2 (en) * 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
EP2536763A1 (en) * 2010-02-19 2012-12-26 Novo Nordisk A/S Activatable constructs
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014040129A1 (en) * 2012-09-12 2014-03-20 The University Of Queensland Protease-based biosensor
SG11201509595PA (en) 2013-05-28 2015-12-30 Dcb Usa Llc Antibody locker for the inactivation of protein drug
EP3044322A4 (en) 2013-09-12 2017-09-06 The University Of Queensland Bimolecular protease-based biosensor
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
US20160362469A1 (en) * 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
JP7073258B2 (ja) 2015-11-19 2022-05-23 レビトープ リミテッド 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完
DK3452591T5 (da) 2016-05-02 2024-09-09 Encodia Inc Makromolekyleanalyse under anvendelse af nukleinsyrekodning
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CN110036034A (zh) 2016-12-09 2019-07-19 西雅图遗传学公司 卷曲螺旋掩蔽的二价抗体
US20210130494A1 (en) * 2017-02-22 2021-05-06 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US11513126B2 (en) * 2017-10-31 2022-11-29 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
JP7582676B2 (ja) 2019-04-30 2024-11-13 エンコディア， インコーポレイテッド 分析物を調製するための方法および関連キット
BR112022024469A2 (pt) * 2020-06-19 2023-01-17 Hoffmann La Roche Molécula biespecífica de ativação de células t ativáveis por protease, polipeptídeo específico de idiotipo, composição farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma molécula biespecífica de ativação de células t ativáveis por protease, molécula biespecífica de ativação de células t ativáveis por protease, uso da molécula biespecífica de ativação de células t ativáveis por protease e método para tratar uma doença em um indivíduo
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
JP7402381B2 (ja) 2020-11-04 2023-12-20 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2023546368A (ja) 2021-05-14 2023-11-02 ジェネンテック， インコーポレイテッド モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849478A (en) * 1986-08-14 1998-12-15 Cashman; Daniel P. Blocked-polymerase polynucleotide immunoassay method and kit
GB9322156D0 (en) * 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
US5468785A (en) * 1994-04-15 1995-11-21 University Of Akron Cobaloxime photoinitiated free radical polymerizations
AU5509296A (en) * 1995-05-03 1996-11-21 Colin Henry Self Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
AU3567099A (en) * 1998-04-16 1999-11-01 Packard Bioscience Company Analysis of polynucleotide sequence
EP1112378A1 (en) * 1998-07-17 2001-07-04 GeneTag Technology, Inc. Methods for detecting and mapping genes, mutations and variant polynucleotide sequences
US6203989B1 (en) * 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
EP1349943A2 (en) * 2001-01-04 2003-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Detection of protein conformation using a split ubiquitin reporter system
US20040097586A1 (en) * 2001-01-30 2004-05-20 Andre Trouet Anti-tumor compounds
US20030082191A1 (en) * 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders

Also Published As

Publication number Publication date
WO2005083431A2 (en) 2005-09-09
WO2005083431A3 (en) 2005-10-20
EP1723418A2 (en) 2006-11-22
US20080107660A1 (en) 2008-05-08
JP2007524105A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
IL182279A0 (en) Angiopoietin-2-specific binding agents
GB0404187D0 (en) Binding agents
IL179661A0 (en) Il-13 binding agents
GB0521991D0 (en) Siglec-9 binding agents
DE602005025924D1 (en) Royl-coa-desaturase
DE602005020252D1 (en) Röhrenförmige prothese
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
DE602004014986D1 (en) Terminal-box
EG23651A (en) Culturama
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
DE602005010905D1 (en) Roboterhandvorrichtung
DE602005011286D1 (en) Pyrazolopyridinderivate
DE502005007040D1 (en) Laryngoskop
DE502005007456D1 (en) Nanoemulsionen
DE602005008719D1 (en) Notinformationsschild
DE602005026795D1 (en) Polythiourethan
DE502004004685D1 (en) Giessmaschine
EP1710096A4 (en) BINDING DEVICE
DE602005010119D1 (en) Roboterhandvorrichtung
DE602005010440D1 (en) Lymerdispersionen
DE502005009795D1 (en) Modulares gelenkprothesensystem
DE602005003029D1 (en) Polyaminoamidmonoepoxyaddukte
DE602005025096D1 (en) Rotationsdämpfer
GB0410627D0 (en) Specific binding members
DE502005010653D1 (en) Eiten

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)